BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32623818)

  • 21. Laboratory monitoring of nusinersen safety.
    Goedeker NL; Gibbons JL; Varadhachary AS; Connolly AM; Zaidman CM
    Muscle Nerve; 2021 Jun; 63(6):902-905. PubMed ID: 33675054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nusinersen for the treatment of spinal muscular atrophy.
    Chiriboga CA
    Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis.
    Fox D; To TM; Seetasith A; Patel AM; Iannaccone ST
    Adv Ther; 2023 Mar; 40(3):903-919. PubMed ID: 36534265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intrathecal catheter and port placement for nusinersen infusion in children with spinal muscular atrophy and spinal fusion.
    Shashi KK; Stone SSD; Berde CB; Padua HM
    Pediatr Radiol; 2021 Dec; 51(13):2588-2595. PubMed ID: 34254153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unilateral interlaminar fenestration on the convex side provides a reliable access for intrathecal administration of nusinersen in spinal muscular atrophy: a retrospective study.
    Wang Z; Feng E; Jiao Y; Zhao J; Chen X; Zhang H; Liang J; Li Z; Cui X; Chen W; Shen J
    Orphanet J Rare Dis; 2023 Nov; 18(1):369. PubMed ID: 38031122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Complex Spine in Children with Spinal Muscular Atrophy: The Transforaminal Approach-A Transformative Technique.
    Towbin R; Schaefer C; Kaye R; Abruzzo T; Aria DJ
    AJNR Am J Neuroradiol; 2019 Aug; 40(8):1422-1426. PubMed ID: 31296522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nusinersen does not improve lung function in a cohort of children with spinal muscular atrophy - A single-center retrospective study.
    Heitschmidt L; Pichlmaier L; Eckerland M; Steindor M; Olivier M; Fuge I; Kölbel H; Hirtz R; Stehling F
    Eur J Paediatr Neurol; 2021 Mar; 31():88-91. PubMed ID: 33711791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model.
    MacCannell D; Berger Z; Kirschner J; Mercuri E; Farrar MA; Iannaccone ST; Kuntz NL; Finkel RS; Valente M; Muntoni F
    CNS Drugs; 2022 Feb; 36(2):181-190. PubMed ID: 35080757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.
    Haché M; Swoboda KJ; Sethna N; Farrow-Gillespie A; Khandji A; Xia S; Bishop KM
    J Child Neurol; 2016 Jun; 31(7):899-906. PubMed ID: 26823478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultrasound assisted lumbar intrathecal administration of nusinersen in adult patients with spinal muscular atrophy: A case series.
    Zanfini BA; Catarci S; Patanella AK; Pane M; Frassanito L; Filipponi E; Mercuri E; Sabatelli M; Draisci G
    Muscle Nerve; 2021 Nov; 64(5):594-599. PubMed ID: 34396547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computed-tomography-guided transforaminal intrathecal nusinersen injection in adults with spinal muscular atrophy type 2 and severe spinal deformity. Feasibility, safety and radiation exposure considerations.
    Spiliopoulos S; Reppas L; Zompola C; Palaiodimou L; Papadopoulou M; Filippiadis D; Palialexis K; Ploussi A; Efstathopoulos E; Tsivgoulis G; Brountzos E
    Eur J Neurol; 2020 Jul; 27(7):1343-1349. PubMed ID: 32250518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrathecal delivery of nusinersen in individuals with complicated spines.
    Cartwright MS; Ward ZT; White EP; West TG
    Muscle Nerve; 2020 Jul; 62(1):114-118. PubMed ID: 32319101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Managing intrathecal administration of nusinersen in adolescents and adults with 5q-spinal muscular atrophy and previous spinal surgery.
    Mendonça RH; Fernandes HDS; Pinto RBS; Matsui Júnior C; Polido GJ; Silva AMSD; Grossklauss LF; Reed UC; Zanoteli E
    Arq Neuropsiquiatr; 2021 Feb; 79(2):127-132. PubMed ID: 33759979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.
    Meylemans A; De Bleecker J
    Acta Neurol Belg; 2019 Dec; 119(4):523-533. PubMed ID: 31388901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nusinersen for Patients With Spinal Muscular Atrophy: 1415 Doses via an Interdisciplinary Institutional Approach.
    Madan E; Carrié S; Donado C; Lobo K; Souris M; Laine R; Beers E; Cornelissen L; Darras BT; Koka A; Riley B; Dinakar P; Stone S; Snyder B; Graham RJ; Padua H; Sethna N; Berde C
    Pediatr Neurol; 2022 Jul; 132():33-40. PubMed ID: 35636280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultrasound-assisted intrathecal injection of nusinersen in a patient with severe vertebral deformity: a case report.
    Nagano T; Sakura S; Imamachi N; Saito Y
    JA Clin Rep; 2020 Aug; 6(1):61. PubMed ID: 32783149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Administration of nusinersen via paramedian approach for spinal muscular atrophy.
    Iwayama H; Wakao N; Kurahashi H; Kubota N; Hattori A; Kumagai T; Okumura A
    Brain Dev; 2021 Jan; 43(1):121-126. PubMed ID: 32773161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.